Christina Rossi has been appointed to CG Oncology’s Board of Directors.
Ms. Rossi is an experienced biopharmaceutical executive leader and board member with an established track record of building and leading exceptional organizations to create value.
Ms. Rossi most recently served as Chief Operating Officer of Blueprint Medicines from 2022 until its acquisition by Sanofi in 2025. Previously, she served as Chief Commercial Officer and has overseen the commercial launches of Blueprint therapies across multiple indications and geographies, including the creation of commercial infrastructure and successful market access efforts in the U.S. and Europe.
This search was conducted and completed by Managing Director Beth Ehrgott.
“At this exciting and critical time for CG Oncology with the company’s recent BLA submission for its lead program, Christy is the perfect addition to the board. Her strategic business and commercial leadership expertise will help guide the organization through a successful launch and ultimate goal to achieve their mission, making a huge difference for patients suffering from bladder cancer,” said Beth Ehrgott, Managing Director, The Alexander Group.
CG Oncology, Inc. (NASDAQ: CGON) is a late-stage clinical biopharmaceutical company dedicated to developing innovative cancer immunotherapies, with a primary focus on bladder cancer.
The Company leverages proprietary oncolytic virus platforms to develop targeted therapies that selectively destroy cancer cells while activating the body’s immune response. The Company has initiated its first BLA submission to the FDA for its lead program, cretostimogene, and is building an organization to support the launch of this innovative oncology product.
With a commitment to scientific innovation and patient-centric development, the Company operates with a strong foundation in clinical research, regulatory engagement, and strategic partnerships.